Yesterday Sven Kili, board member and CMO of Swedish company Xintela visited Biostock’s studio. Xintela works within the fields of regenerative medicine and cancer, focusing particularly on cartilage damage and aggressive brain tumours. These are areas where the need for new treatment methods is great and Sven Kili told BioStock more about how Xintela can contribute to this through its patented technology. Kill also discussed Xintela’s studies, the importance of the company’s own GMP facility for production of stem cells as well as upcoming milestones.
Watch the interview with Sven Kili below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.